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1Preeclampsia affects ≈3% of all pregnancies1 with associ-ated maternal complications of renal injury, hepatic injury, 
stroke, hemorrhage, and eclampsia, as well as fetal complica-
tions, including growth restriction and stillbirth. Half of the 
women with severe preeclampsia deliver preterm and one in 
20 stillbirths without congenital abnormality occur in women 
with preeclampsia.2
Placental dysfunction underlies the cause of pregnancies 
complicated by preeclampsia and their associated adverse 
pregnancy outcomes.3,4 In vivo assessment of placental func-
tion in clinical practice is currently limited to indirect assess-
ments as a proxy for placental function, including measures of 
fetal growth and Doppler umbilical artery velocimetry.
Objective in vivo assessment of placental structure and 
quantification of function may help elucidate the pathophysi-
ology in those pregnancies with established preeclampsia and 
provide a potential tool to inform prognosis. Quantitative non-
invasive in vivo assessment of the placenta can be achieved 
with magnetic resonance imaging (MRI). T2* mapping 
probes placental oxygenation as the paramagnetic properties 
of deoxyhemoglobin cause magnetic field distortions and a 
faster T2* decay (ie, reduced transverse relaxation time) than 
oxyhemoglobin. Hypoxic tissues, therefore, have a reduced 
T2* value (blood oxygen level dependency effect). In addition 
to oxygenation, T2* values are also affected by lipid content, 
calcium content, extracellular fluid volume, and surface area, 
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Abstract—Placental dysfunction underlies the cause of pregnancies complicated by preeclampsia. The use of placental 
magnetic resonance imaging to provide an insight into the pathophysiology of preeclampsia and thus assess its potential 
use to inform prognosis and clinical management was explored. In this prospective observational cohort study, 14 women 
with preterm preeclampsia and 48 gestation-matched controls using 3-Tesla magnetic resonance imaging at median of 
31.6 weeks (interquartile range [IQR], 28.6–34.6) and 32.2 weeks (IQR, 28.6–33.8), respectively, were imaged. The 
acquired data included T2-weighted images and T2* maps of the placenta, the latter an indicative measure of placental 
oxygenation. Placentae in women with preeclampsia demonstrated advanced lobulation, varied lobule sizes, high 
granularity, and substantial areas of low-signal intensity on T2-weighted imaging, with reduced entire placental mean T2* 
values for gestational age (2 sample t test, t=7.49) correlating with a reduction in maternal PlGF (placental growth factor) 
concentrations (Spearman rank correlation coefficient 0.76) and increased lacunarity values (t=3.26). Median mean T2* 
reduced from 67 ms (IQR, 54–73) at 26.0 to 29.8 weeks’ gestation to 38 ms (IQR, 28–40) at 34.0 to 37.9 weeks’ gestation in 
the control group. In women with preeclampsia, median T2* was 23 ms (IQR, 20–23) at 26.0 to 29.8 weeks’ gestation and 
remained low (22 ms [IQR, 20–26] at 34.0–37.8 weeks’ gestation). Histological features of maternal vascular malperfusion 
were only found in placentae from women with preeclampsia. Placental volume did not differ between the control group 
and women with preeclampsia. Placental magnetic resonance imaging allows both objective quantification of placental 
function in vivo and elucidation of the complex mechanisms underlying preeclampsia development.  (Hypertension. 
2020;75:00-00. DOI: 10.1161/HYPERTENSIONAHA.120.14701.) • Data Supplement
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the latter contributed by cellular membranes, intracellular or 
extracellular macromolecules.5 Studies have shown a linear 
reduction in mean T2* values in uncomplicated pregnancies 
with increasing gestation6 and an increase in placental T2* 
with maternal hyperoxia.7,8 Lower mean T2* values have been 
found in placentae of pregnancies complicated by fetal growth 
restriction9,10; however, to our knowledge, no published study 
has reported T2* evaluation in women with preeclampsia.
The aim of this study was to explore the use of placental 
MRI to provide an insight into the pathophysiology of pree-
clampsia and thus assess its potential use to inform prognosis 
and clinical management.
Methods
The data set will be made available from the corresponding author 
upon reasonable request, with input from the investigator group 
where applicable, and in accordance with the data sharing policies of 
King’s College London. The acquisition and processing pipeline for 
T2* mapping has been published and is freely available.6
Study Design
This prospective observational cohort study was undertaken at St 
Thomas’ Hospital, London, a tertiary-level maternity unit. Women 
with preeclampsia were approached in person antenatally. Women in 
the control group were recruited at their routine 20-week anomaly 
scan or self-referred to take part in the study. All women in the study 
gave written informed consent.
Follow-up was until delivery. Prospectively specified data col-
lection included baseline demographic characteristics, maternal, and 
neonatal outcomes.
Women were considered for inclusion in the study if they had a 
singleton pregnancy, were clinically stable, over 16 years of age, not 
claustrophobic with no contraindication for MRI. They were assessed 
for our Philips 3T Achieva scanner; given the 60 cm scanner bore 
size, women also had to have a body mass index <30 kg/m2 and ab-
dominal girth <130 cm.
Preeclampsia was prospectively defined using the international 
consensus definition.11 This was women who developed gesta-
tional hypertension accompanied by one or more of the following 
new-onset conditions at or after 20 weeks’ gestation: proteinuria, 
acute kidney injury, liver involvement, neurological complica-
tions, hematological complications, and uteroplacental dysfunction. 
Preeclampsia superimposed on chronic hypertension was defined 
as the additional presence of maternal organ dysfunction consist-
ent with preeclampsia. PlGF was not used as part of the clinical or 
research definition. Clinical management of hypertensive women 
was according to national guidelines,12 with responsibility under the 
attending consultant.
Women in the control group fulfilled the following criteria: no 
diagnosis of a hypertensive disorder at enrollment and until de-
livery, no significant past medical history, no pregnancy compli-
cations (including gestational diabetes mellitus), delivery at term 
with birthweight between the third and 97th centile (calculated us-
ing International Fetal and Newborn Growth Consortium for the 
21st Century version 1.3.5)13 thus excluding potential confound-
ers of placental change.14–17 These women were gestation matched 
to women with preeclampsia and selected from a research study 
(Placenta Imaging Project, REC 16/LO/1573, IRAS 201609), the 
primary objective of which is to develop a novel magnetic reso-
nance approach to assess growth and development of the human 
placenta. Gestation matching was achieved masked to values de-
rived from MRI so that 3 women with uncomplicated pregnancies 
with imaging within 2 weeks of the gestation at which each woman 
with preeclampsia was imaged were chosen for comparison.
No formal sample size was calculated for power of outcome vari-
ables as this was an exploratory study describing a novel technique in 
technology development application. The study was approved by the 
Fulham Research Ethics Committee, REC 16/LO/1573.
Magnetic Resonance Imaging
MRI was performed on a clinical Philips 3T Achieva with a 32-chan-
nel cardiac coil. Women underwent MRI on up to 2 occasions, a min-
imum of 2 weeks apart and at any time point between their clinically 
routine anomaly ultrasound scan (at around 18–22 weeks’ gestation) 
and delivery. Imaging was performed supine with supported lower 
limbs and shoulders after a period of 3 minutes in left lateral. Total 
imaging time did not exceed 1 hour, and women were offered a break 
of under 30 minutes halfway through the scan. Maternal assessments 
during imaging included blood pressure measurements every 10 
minutes with continuous maternal heart rate and oxygen saturation 
monitoring. All scans had an obstetrician or specialist midwife pre-
sent throughout. No pharmacological sedation was used.
Image-based shimming was achieved using an in-house tool, after 
acquiring a B0 map, to reduce the effect of inhomogeneities in the 
magnetic field. Multi-echo gradient echo, echo planar imaging at 3 
mm3 resolution was performed with free breathing and took <1 mi-
nute, with the whole placenta covered within 60 slices (5 echo times: 
13.81 ms/70.40 ms/127.00 ms/183.60 ms/240.2 ms, repetition time=3 
seconds, SENSitivity Encoding=3, halfscan=0.6). One scan was per-
formed at 2 mm3 resolution. Echo times result from the chosen EPI 
train characteristics. Thereby, the intra-echo spacing was chosen to 
minimize acoustic noise and the interecho spacing as the minimal 
possible spacing. Parameters were kept constant between women 
with preeclampsia and the control group.
A long TE (180 ms) T2-weighted single-shot turbo spin-echo se-
quence of the whole uterus (thereby including placenta) was acquired 
in coronal and sagittal planes to the mother with repetition time=16 
seconds, SENSitivity Encoding=2.5, and partial Fourier 0.625. In-
plane resolution was 1.5 mm × 1.5 mm, slice thickness 2.5 mm with 
an overlap of 0.5 mm. The field of view was 300×360×[100−200] 
mm (coronal) and 300×300×340 mm (sagittal) in the FH×RL×AP 
directions, respectively. Structural images of the fetal brain were re-
ported and available to the clinical team. Data quality was assessed 
to exclude sequences with uterine contractions. Visual analysis 
examined the signal intensity across the placenta and whether the 
presence of placental lobules and septae were visually apparent. The 
signal intensity within lobules was visually assessed for granularity 
with high granularity defined as the presence of both high- and low-
signal intensity within individual lobules.
An in-house Python script by J. Hutter produced T2* maps. The 
placenta was manually segmented by an experienced observer (A.E.P. 
Ho) using ITK-SNAP. A further processing step calculated mean pla-
cental T2*and lacunarity. Lacunarity values reflect the spatial distri-
bution of gaps of a specific size within lobules. The acquisition and 
processing pipeline for T2* imaging has been described previously 
and shown to have good reproducibility with a high Dice coefficient 
between observers who segmented the placenta.6,18
Placental Growth Factor
Venepuncture blood sampling was performed as close to MRI as fea-
sible, usually on the same day (in 32 out of 43 available samples). Six 
milliliters of blood were drawn into a bottle containing ethylenedia-
mine tetra-acetic acid, transported to the laboratory within 1 hour and 
underwent centrifugation at 1400g (rcf) for 10 minutes at 4°C. PlGF 
was quantified using the Triage PlGF Test (Alere, San Diego, CA) 
according to the manufacturer’s instructions while masked to both 
cohort and clinical outcome. The clinical team did not receive the re-
sult; however, in 5 women with preeclampsia PlGF was performed as 
part of their clinical care as diagnostic workup12 when preeclampsia 
was suspected.
Placental Histology
Following delivery and where available, placentas underwent histolog-
ical examination according to local protocols at the Cellular Pathology 
Department, St Thomas’ Hospital. Placentas were fixed in 10% buff-
ered formalin and trimmed of both umbilical cord and membranes for 
placenta weight. The following areas were sampled and then embed-
ded in paraffin: 2 transverse sections of the umbilical cord, one roll of 
membranes (including rupture site), 2 to 3 full-thickness blocks of the 
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placental parenchyma away from the placental edge (including fetal and 
maternal surfaces). Additional areas were sampled depending on mac-
roscopic findings. Paraffin-embedded tissue sections were then cut into 
4-micron sections, deparaffinized and stained with hematoxylin and eosin 
before histological examination. A clinical report for all placentas sub-
mitted was issued, in accordance with local hospital reporting guidelines. 
Histological slides were then reexamined for features of maternal vascular 
malperfusion, fetal vascular malperfusion, and acute chorioamnionitis by 
histopathologists who were masked to the pregnancy outcome; features 
were identified and classified using guidelines from the International 
Placental Pathology Consensus Meeting, Amsterdam 2014.19 Any dis-
crepancies between reporting histopathologists were reexamined (again 
masked to the pregnancy outcome) and a consensus opinion was reached.
Statistical Methods
In uncomplicated pregnancies, gestation-adjusted reference ranges 
for placental mean T2* and lacunarity values were established after 
examining a range of possible models using the Stata command 
-xriml-,20 and 10% to 90% reference range established. A 2 sample 
t test was used to compare placental mean T2* and lacunarity (z 
scores) between these groups, using robust standard errors to allow 
for clustering given 2 women were imaged twice in the preeclamptic 
group. Multiple regression, adjusting for gestation, was used to com-
pare placental volume between uncomplicated pregnancies and those 
with preeclampsia.
Spearman rank correlation coefficient was calculated to evaluate 
the relationship between PlGF and placental mean T2*. Women who 
declined venepuncture were not included in the analysis. Birthweight 
centiles were calculated using International Fetal and Newborn 
Growth Consortium for the 21st Century version 1.3.5.13 Pregnancy 
outcome data were available for all women in both cohorts. Statistical 
analysis was performed using Stata version 15.1 (StataCorp, College 
Station, TX).
Results
Enrollment was between May 2017 and April 2019. Of the 
14 women with preeclampsia who were recruited, all 14 
women were imaged (none of whom had uterine contractions 
during imaging) with 48 gestation-matched controls. Five of 
14 women (36%) had superimposed preeclampsia on a back-
ground of chronic hypertension (Table 1). Women with pre-
eclampsia had higher blood pressures both prior and during 
imaging and had lower concentrations (Table 1). Of women 
with available data on hemoglobin concentrations, the median 
hemoglobin at booking was 123 g/L (interquartile range, 121–
131) and at 28 weeks’ gestation was 117 g/L (interquartile 
range, 113–122; n=37 women). In women with preeclampsia, 
the median hemoglobin at booking was 124 g/L (interquartile 
range, 120–131) and at 28 weeks’ gestation was 120 g/L (in-
terquartile range, 110–137; n=10 women).
Time from MRI to delivery was shorter in women with 
preeclampsia (Table 2). In the preeclamptic cohort, 11 women 
delivered preterm with 7 before 34 weeks’ gestation (Table 2, 
Table S1 in the Data Supplement) while all women in the con-
trol cohort delivered after 37 weeks’ gestation. Twenty-one 
placentae from the control group and 12 placentae from the 
preeclamptic group underwent histological examination, with 
double reading by 2 histopathologists to standardized proto-
cols, masked to clinical outcome (Table 3). On assessment, 
there were no features of maternal vascular malperfusion on 
placental histological examination in the control group while 
10 of 12 placentae examined from women with preeclampsia 
did (Table 3). In the 2 placentae from preeclamptic women 
with no features of maternal vascular malperfusion, delivery 
Table 1. Characteristics at Booking and Enrollment
Booking and Enrollment 
Characteristics
Control  
n=48
Preeclampsia 
n=14
At booking
  Maternal age, y, median (IQR) 33 (32–36) 32 (26–37)
  Gestational age on day of MRI, 
wk, median (IQR)
31.6 (28.6–34.6) 32.2 (28.6–33.8)
  Body mass index, kg/m2, 
median (IQR)
22 (21–24) 25 (23–25)
  Nulliparous 24 (50) 6 (43)
  White ethnicity 44 (92) 8 (57)
  Black ethnicity 1 (2) 3 (21)
  Asian ethnicity 2 (4) 0
  Chinese 0 3 (21)
  Mixed ethnicity 1 (2) 0
  Current smoking 1 (2) 0
  Quit smoking before pregnancy 4 (8) 4 (29)
  Never smoked 43 (90) 10 (71)
  Previous preeclampsia 0 3 (21)
  Chronic hypertension 0 5 (36)
  Gestational diabetes mellitus 0 2 (14)
  Inflammatory bowel disease 0 2 (14)
  Intrahepatic cholestasis of 
pregnancy
0 1 (7)
At enrollment on day of MRI
  Aspirin 4 (8) 8 (57)
  No oral antihypertensive agent 48 (100) 2 (14)
  1 oral antihypertensive agent 0 5 (36)
  2 or more oral antihypertensive 
agents
0 7 (50)
Placental growth factor, pg/mL, 
median (IQR)
419 (102–815) <12(<12–<12))
Placental growth factor <100 pg/
mL
7/29 (24) 14/14 (100)
Placental growth factor <12 pg/mL 0 12/14 (86)
Sitting blood pressure on day of MRI
  Systolic, mm Hg, median (IQR) 103 (99–111) 141 (138–145)
  Diastolic, mm Hg, median (IQR) 61 (55–64) 91 (87–98)
  Mean arterial pressure, mm Hg, 
median (IQR)
75 (70–80) 108 (104–113)
Supine blood pressure during MRI
  Systolic, mm Hg, median of 
individual’s median (IQR)
98 (91–103) 127 (124–130)
  Diastolic, mm Hg, median of 
individual’s medians (IQR)
58 (54–64) 80 (77–87)
  Mean arterial pressure, mm Hg, 
median of individual’s medians 
(IQR)
72 (67–76) 94 (93–100)
Values given as a number (percentage) unless stated otherwise. IQR indicates 
interquartile range; and MRI, magnetic resonance imaging.
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occurred after 37 weeks’ gestation with normal birthweight 
centiles. There were no features of fetal vascular malperfusion 
on placental histopathologic examination in either cohort.
Example T2-weighted images from the control and pre-
eclamptic cohorts are shown in Figure 1, with areas of high 
signal on T2-weighted imaging corresponding to long T2* 
and low signal on T2-weighted imaging corresponding to 
short T2* values. In the control cohort, placental lobularity 
(the visual presence of lobules, ie, presumed functional units) 
was more apparent with increasing gestational age at imaging. 
The placental lobules were of low granularity (ie, consistent 
signal intensity within each lobule). Compared to gestation-
matched controls, the placentae in women with preeclampsia 
showed more marked lobularity (Figure 1, with numerical 
data given in Table S2 in the Data Supplement), variable 
lobule size and high granularity with a decline in T2* towards 
lobule periphery. In addition, the placentae in women with 
preeclampsia had substantial additional areas of low-signal 
intensity (Figure 1).
With increasing gestation, placental mean T2* values 
decreased linearly in the control cohort (Figure 2, Table S2 
in the Data Supplement). In women with preeclampsia, 13 of 
14 cases had placental mean T2* values lower than the 10th 
centile of normal values derived from the gestation-matched 
control cohort (2 sample t test, t=7.49 versus controls). One 
woman with preeclampsia and placental mean T2* value 
within normal range delivered a baby of normal birthweight 
centile at 37 weeks’ gestation, with normal placental histolog-
ical examination. Women with preeclampsia had higher pla-
cental lacunarity values (2 sample t test, t=3.83) on T2* and in 
the control group, lacunarity increased with increasing gesta-
tion (Figure 3A, Table S2 in the Data Supplement). Placental 
mean T2* positively correlated (Spearman rank correlation 
coefficient of 0.76) with PlGF concentration (Figure 3B). 
Placental volume did not differ significantly between women 
in the control group and women with preeclampsia (Figure S1 
in the Data Supplement). Two women with preeclampsia were 
imaged twice, 2 weeks apart (as indicated in the participant 
flow diagram in Figure S2 in the Data Supplement).
Discussion
Using a well-tolerated optimized MRI protocol,18 this study has 
provided a magnetic resonance whole placental phenotype in 
pregnancies complicated by preeclampsia, and these findings 
have been compared to a gestation-matched control cohort.
Table 2. Maternal and Neonatal Outcomes
Maternal and Neonatal Outcome 
Variables
Control  
n=48 Preeclampsia n=14
Time from MRI to delivery, d, 
median (IQR)
65 (37–84) 10 (6–19)
Onset of delivery
  Spontaneous 31 (65) 0
  Induction 9 (19) 8 (57)
  Prelabour cesarean 8 (17) 6 (43)
Primary reason for induction or prelabour cesarean*
  Maternal indication 4/17 (24) 7/14 (50)
  Fetal indication 13/17 (76) 7/14 (50)
Delivery
  Livebirth 48 (100) 14 (100)
  Gestational age at delivery, 
weeks, median, IQR
40.4 (39.2–41.1) 34.0 (30.0–36.5)
  Spontaneous vaginal delivery 24 (50) 1 (7)
  Assisted vaginal delivery 9 (19) 1 (7)
  Elective prelabour cesarean 
section
7 (15) 0
  Urgent cesarean section 8 (17) 12 (86)
  Preterm birth <37/40 0 11 (79)
  Preterm birth < 34/40 0 7 (50)
  Birthweight, g, median (IQR) 3460 (3109–3726) 1635 (926–2157)
  Birthweight centile, centile, 
median (IQR)
65 (32–80) 7 (3–17)
  5 min Apgar score ≥7 47 (98) 13 (93)
  Respiratory support required 
in delivery room
4 (8) 6 (43)
Number admitted to neonatal 
unit for ≥48 h
1 (2) 12 (86)
Length of stay in intensive care, 
day, median, IQR
0 8 (1–10)
Length of stay in high 
dependency, day, median, IQR
0 1 (0–4)
Length of stay in special care, 
day, median, IQR
3 7 (2–16)
Primary indication for neonatal unit admission
  Prematurity 0 7/12 (58)
  Fetal growth restriction/small 
for gestational age
0 2/12 (17)
  Respiratory disease 0 1/12 (8)
  Suspected sepsis 0 1/12 (8)
  Hypoglycemia 0 1/12 (8)
Values given as a number (percentage) unless stated otherwise. IQR indicates 
interquartile range; MRI, magnetic resonance imaging.
*Full details given in Table S1 in the Data Supplement.
Table 3. Placental Histology Findings
Placental Histology Characteristics Control Preeclampsia
No. of placentae assessed 21 12
Placental weight, g, median (IQR) 454 (403–562) 346 (188–458)
Fetal-placental birthweight ratio, 
median (IQR)
7.4 (7.1–7.7) 5.6 (4.8–5.9)
Maternal vascular malperfusion 
features
0 10 (83)*
Fetal vascular malperfusion features 0 0
Chorioamnionitis features 10 (48) 2 (17)
Values given as a number (percentage) unless stated otherwise. IQR indicates 
interquartile range.
*Two of the 12 placentas in the preeclamptic cohort did not have maternal 
vascular malperfusion features and delivered at term.
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On visual inspection of T2-weighted imaging, placentae 
from women with preeclampsia showed substantial areas of 
low-signal intensity, advanced lobularity, and high granularity 
within lobules. Objective magnetic resonance quantification 
of these placentae also showed a reduced entire placental 
mean T2* for gestational age, with higher lacunarity values 
compared with controls. The placental volume in the pree-
clamptic group was not significantly different to those in the 
control group.
A major strength of this study is the novelty of the im-
aging undertaken in women with preeclampsia, partic-
ularly assessing placental mean T2* with a measure of 
texture (lacunarity values) in a cohort of women with pre-
eclampsia. Visual analysis can be easily adopted in clinical 
practice, without the need for further processing of imaging 
data. However, while simple visual analysis of T2-weighted 
images alone showed characteristic features of the placenta 
in women with preeclampsia, T2* information obtained 
Figure 1. T2-weighted imaging and T2* maps. A, Example T2-weighted imaging and T2* maps in coronal and sagittal planes across gestation. B, Features of 
T2-weighted imaging in women with preeclampsia.
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objective quantifiable information allowing comparisons be-
tween women, among which the whole placental mean T2* 
was the most discriminatory in identifying women with pre-
eclampsia. Rapid acquisition of T2* images (in <1 minute) 
increases potential for clinical applicability and used a tech-
nique which has been previously demonstrated to be repro-
ducible.18 Multi-Echo acquisition was chosen as it freezes 
motion per slice. All data required for the T2* fit per slice 
was acquired in <250 ms. The motion occurring between 
slices does not influence the fitting process.
Our robust safety approach included blood pressure mon-
itoring with continuous maternal heart rate and oxygen sat-
uration during imaging. A strength of this study is that we 
have imaged women at a range of gestations (25–37 weeks) 
in our preeclamptic cohort with anticipated complications, 
including fetal growth restriction, iatrogenic preterm de-
livery, neonatal unit admission, and low birthweight centiles. 
Limitations included being unable to image women with a 
body mass index greater than 30 kg/m2 due to size limitations 
of our 3T Achieva scanner bore; however, we have been able 
to image across the third trimester, thus increasing applica-
bility to a clinical context.
In uncomplicated pregnancies, T2-weighted visual anal-
ysis shows increasing lobulation with widening of the low-
signal intensity septal areas around lobules. This and previous 
studies have shown that this visual maturation corresponds 
to a reduction in mean T2* values across the placenta.6,10,21,22 
Mean T2* values are consistent with previously reported stud-
ies18; however, values are inherently affected by magnetic field 
strength, and there remains a lack of literature reporting mean 
T2* in uncomplicated pregnancies at 3 Tesla.23 The placental 
volume is derived from a conservative manual segmentation 
of the T2* maps to ensure only placental tissue sampled, and 
thus is smaller than previously reported in the literature where 
volume is derived from T2-weighted imaging.24,25
Our findings of low placental mean T2* values in preg-
nancies complicated by preeclampsia are consistent with a 
previous smaller study10 in which T2* values were examined 
in 4 women with fetal growth restriction, one of whom had co-
existing preeclampsia. Another study also examined T2* in a 
mixed cohort of 33 women (reported as R2*=1/T2*) at earlier 
gestations (before 24 weeks’ gestation), including 2 women 
with fetal growth restriction and one with preeclampsia.21 
Mean R2* values in women with fetal growth restriction were 
similar to uncomplicated pregnancies. However, these women 
were imaged during early second trimester and all delivered at 
term thus perhaps suggesting a different disease mechanism 
in preterm preeclampsia and term preeclampsia. In our study, 
albeit a small sample size, co-existing fetal growth restriction 
in women with preeclampsia did not appear to further impact 
placental mean T2* values. Recent in vivo MRI in women 
with preeclampsia using a different imaging parameter of pla-
cental perfusion fraction (rather than T2* mapping) showed a 
difference between early- and late-onset preeclampsia and a 
decreased fraction with increasing gestation in controls cor-
relating to maternal biomarkers.26,27
Contrast-enhanced imaging in Rhesus macaques has pre-
viously demonstrated a slow spread of signal intensity en-
hancement from a spiral artery across lobule to periphery in 
a naturally occurring fetal growth restriction case.28 No con-
trast was used in our study; however, we demonstrated a fall in 
signal intensity from the center to the periphery of lobules in 
women with preeclampsia. Previous studies have not included 
maternal biomarker analysis, while we have shown that all 
women with a PlGF <12 pg/mL had a mean T2* lower than 
gestation-matched controls.
The striking visual differences between women with pree-
clampsia and our control cohort on T2-weighted imaging and 
quantitative T2* values provide a magnetic resonance pla-
cental phenotype in preeclampsia. Marked widening of low-
signal septal areas and accelerated maturation of lobules in 
the placentae of women with preeclampsia suggests areas of 
nonfunctioning or poorly functioning tissue. This is supported 
by detailed histological analysis which showed that 10 of 12 
Figure 2. Scatterplot of placental mean T2* 
against gestational age at imaging, lines 
representing 10th, 50th, and 90th centiles. 
Actual placental mean T2* values given in Table 
S2 in the Data Supplement.
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placentae from women with preeclampsia had evidence of 
maternal vascular malperfusion. Areas of low-signal intensity 
on T2-weighted imaging, therefore, likely reflect a poorly per-
fused and poorly oxygenated placenta with a corresponding 
short T2*, also reflected in low maternal PlGF concentrations. 
In a healthy placenta, these low-signal intensity areas are con-
sistently between lobules and likely to represent normal sep-
tae with low oxygenation. In abnormal placentae, the areas of 
low-signal intensity on T2 are different in distribution, size 
and shape, suggesting poorly oxygenated areas extending be-
yond the normal septae. More detailed histology to selectively 
sample these areas would further elucidate any structural dif-
ferences. All women had hemoglobin concentrations within 
normal limits and thus this is unlikely to have substantially 
affected T2* values. Within lobules, there are regional T2* 
differences with a marked decline in T2* towards the lobule 
periphery in preeclampsia. This could be explained by a re-
duction in perfusion of the lobule periphery with oxygenated 
blood following ischemic reperfusion injury from high-pres-
sure flow in poorly remodeled spiral arteries. The peripheral 
areas of lobules may be more vulnerable to damage, giving 
rise to the areas of short T2* distal from central arteries. High 
lacunarity values in women with preeclampsia further support 
the visual phenotype seen on both T2-weighted imaging and 
T2* maps where there is high granularity within individual 
lobules and heterogeneity across the placenta.
More detailed placental histology, biomarkers relating to 
placental oxygenation and diffusion MRI may yield further in-
sight into the pathophysiology of preeclampsia in conjunction 
with placental T2* mapping. While the relationship between 
concentration of deoxygenated hemoglobin and T2* values 
is well established (BOLD effect), it does not allow absolute 
quantification of oxygen concentration. T2* depends addi-
tionally on geometry, saturation, hemoglobin concentration.
A larger sample size of women with preeclampsia encom-
passing those with and without co-existing fetal growth 
restriction and those with early and late onset would be ben-
eficial to examine potential differing mechanisms that result 
in additional fetal morbidity. Placental MRI may demon-
strate different phenotypes in these subgroups, aligned with 
different placental histological findings, and require further 
elucidation. Further characteristics of interest would include 
the presence of other comorbidities, use of antihypertensive 
medication and aspirin usage. It would be advantageous to 
Figure 3. MRI derived measures and placental 
growth factor concentrations in both groups 
(control and preeclampsia). A, Scatterplot of 
lacunarity measure (derived from T2* mapping) 
against gestational age at imaging. Actual 
placental lacunarity values given in Table S2 in 
the Data Supplement. B, Scatterplot of PlGF 
(placental growth factor; sample taken within 
2 wk of magnetic resonance imaging) against 
placental mean T2* (derived from T2* mapping).
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image using a wide bore scanner to encompass those women 
in whom a high body mass index and girth is more prevalent. 
Further studies could be useful to investigate the potential role 
of PlGF (and other maternal serum biomarkers of placental 
function, alongside conventional ultrasound parameters) for 
triage of clinically higher risk women in whom placental MRI 
may be beneficial. However, the 2 modalities (biomarkers and 
MRI) may be providing complementary predictive and mech-
anistic information.
Perspectives
Our study using T2-weighted imaging, T2* mapping and ma-
ternal PlGF concentrations has quantitatively demonstrated a 
placental phenotype in preeclampsia that has helped to sup-
port prevailing theories of complex mechanisms underlying 
placental dysfunction in preeclampsia. Further studies to de-
termine whether there is a potential role for predicting the 
subsequent development of preterm preeclampsia in high-risk 
groups (eg, those with chronic hypertension, gestational hy-
pertension) or women undergoing a fetal MRI for other indi-
cations (such as fetal congenital cardiac abnormalities or fetal 
growth restriction) would be of interest. Future applications of 
T2* mapping may include monitoring of high-risk pregnan-
cies to aid clinical management decisions or measuring effec-
tiveness of new therapies in preeclampsia that aim to target 
underlying oxidative mechanisms.
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What Is New?
•	Using in vivo magnetic resonance imaging to quantify placental function, 
we have evaluated and demonstrated a placental phenotype in women 
with pregnancies complicated by preeclampsia.
•	Techniques include T2* mapping as an indicative measure of placental 
oxygenation and the use of lacunarity to quantify the spatial distribution 
of gaps of a given size across a region of interest.
•	The placentae of women with preeclampsia have low mean T2* and high 
lacunarity values.
What Is Relevant?
•	Preeclampsia is a hypertensive disorder of pregnancy-associated with 
adverse pregnancy outcome.
•	Placental dysfunction underlies the cause of these pregnancies.
•	Magnetic resonance imaging provides objective quantification of placen-
tal function in vivo and elucidation of complex mechanisms underlying 
preeclampsia development, thus has potential to inform prognosis and 
clinical management.
Summary
This prospective observational cohort study has used T2-weighted 
imaging, T2* mapping and maternal PlGF (placental growth factor) 
concentrations to quantitatively demonstrate a placental phenotype 
in preeclampsia.
Novelty and Significance
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